Literature DB >> 1312660

Early appearance and biphasic kinetics of IgG antibody against hepatitis C virus protein C100-3.

C F Yoshida1, O A Soares, H G Schatzmayr, A Uy, W H Gerlich.   

Abstract

Antibody to recombinant hepatitis C virus (HCV) protein C100 (anti-C100) was measured for a period of 6 months by enzyme immunoassay in nine prospectively followed non A-nonB (NANBH) cases which occurred after cardiac surgery at a hospital in Rio de Janeiro (Brazil). At least seven cases were infected with HCV; four of these developed chronic hepatitis as shown in liver biopsy at the 6th month after transfusion. The first elevation of alanine aminotransferase (ALT) occurred between 15 and 45 days after transfusion and ALT values remained elevated for 45 days in resolving hepatitis, whereas in chronic cases fluctuation levels were observed until the end of the study. Anti-C100 appeared after 15 to 30 days, decreased after some weeks, and rose finally to high concentrations except in one resolving case where it disappeared. We conclude that both in acute and chronic hepatitis C an early antibody response occurs which may, however, be undetectable in some cases. After several months all chronic and some resolving cases develop a second stronger response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312660     DOI: 10.1007/bf00191549

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  18 in total

1.  Epidemiology of hepatitis C virus. A preliminary study in volunteer blood donors.

Authors:  C E Stevens; P E Taylor; J Pindyck; Q L Choo; D W Bradley; G Kuo; M Houghton
Journal:  JAMA       Date:  1990-01-05       Impact factor: 56.272

2.  Prevalence of antibodies to recombinant hepatitis C virus protein C100-3 and of elevated transaminase levels in blood donors from Northern Germany.

Authors:  G Caspari; J Beyer; K Richter; W H Gerlich; H Schmitt
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

Review 3.  Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features.

Authors:  J L Dienstag
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

4.  Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood.

Authors:  D E Koziol; P V Holland; D W Alling; J C Melpolder; R E Solomon; R H Purcell; L M Hudson; F J Shoup; H Krakauer; H J Alter
Journal:  Ann Intern Med       Date:  1986-04       Impact factor: 25.391

5.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

7.  Serodiagnosis of hepatitis C virus (HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus.

Authors:  J Chiba; H Ohba; Y Matsuura; Y Watanabe; T Katayama; S Kikuchi; I Saito; T Miyamura
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

8.  Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein.

Authors:  B Hosein; C T Fang; M A Popovsky; J Ye; M Zhang; C Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

9.  Detection of hepatitis C viral sequences in blood donations by "nested" polymerase chain reaction and prediction of infectivity.

Authors:  J A Garson; R S Tedder; M Briggs; P Tuke; J A Glazebrook; A Trute; D Parker; J A Barbara; M Contreras; S Aloysius
Journal:  Lancet       Date:  1990-06-16       Impact factor: 79.321

10.  Detection of hepatitis C viral sequences in non-A, non-B hepatitis.

Authors:  A J Weiner; G Kuo; D W Bradley; F Bonino; G Saracco; C Lee; J Rosenblatt; Q L Choo; M Houghton
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.